ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates
June 10, 2024 06:30 ET
|
ProKidney
Interim results of REGEN-007 Phase 2 trial show stabilization of kidney function for 18 monthsSafety profile consistent with prior studies and comparable to kidney biopsyResumed manufacturing and both...
Fortrea Finaliza Transferência das Unidades Endpoint Clinical e Patient Access para a Arsenal Capital Partners
June 05, 2024 16:52 ET
|
Fortrea Holdings Inc
DURHAM, N.C., June 05, 2024 (GLOBE NEWSWIRE) -- A Fortrea (Nasdaq: FTRE) (a “Empresa”), uma organização líder global de pesquisa por contrato (CRO), anunciou hoje que finalizou a alienação dos...
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 05, 2024 07:00 ET
|
G1 Therapeutics
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant
June 05, 2024 01:30 ET
|
OSE Immunotherapeutics
OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant At the American Transplant Congress 2024 (June 1-5...
Fortrea Melengkapkan Penyahlaburan daripada Perusahaan Endpoint Clinical dan Patient Access kepada Arsenal Capital Partners
June 04, 2024 22:05 ET
|
Fortrea Holdings Inc
DURHAM, N.C., June 05, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) Organisasi penyelidikan kontrak global peneraju (“CRO”) hari ini mengumumkan bahawa ia telah melengkapkan penyahlaburan aset...
Fortrea Menyelesaikan Divestasi Bisnis Endpoint Clinical dan Patient Access ke Arsenal Capital Partners
June 04, 2024 22:05 ET
|
Fortrea Holdings Inc
DURHAM, N.C., June 05, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), sebuah organisasi riset berbasis kontrak (CRO) global terkemuka, hari ini mengumumkan telah menyelesaikan divestasi aset yang...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 04, 2024 07:00 ET
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., June 04, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted...
Fortrea Completes Divestiture of Endpoint Clinical and Patient Access Businesses to Arsenal Capital Partners
June 04, 2024 07:00 ET
|
Fortrea Holdings Inc
DURHAM, N.C., June 04, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) a leading global contract research organization (“CRO”), today announced it has completed the divestiture of assets relating to...
Scorpius Holdings and Beyond Imagination Announce Trailblazing Partnership to Utilize Autonomous AI-Powered Humanoid Robots for American Biomanufacturing
June 03, 2024 08:00 ET
|
Scorpius Holdings, Inc.
Collaboration aims to enhance biomanufacturing reliability, scalability and efficiency Autonomous humanoids designed to complement human labor and enhance productivity through 24/7 operational...
Fortrea to Present at the Jefferies Global Healthcare Conference
June 03, 2024 07:00 ET
|
Fortrea Holdings Inc
DURHAM, N.C., June 03, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced that Chairman and Chief Executive Officer, Tom Pike and...